MESA LABORATORIES INC (MLAB) Fundamental Analysis & Valuation

NASDAQ:MLAB • US59064R1095

Current stock price

80 USD
-2.52 (-3.05%)
At close:
80 USD
0 (0%)
After Hours:

This MLAB fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. MLAB Profitability Analysis

1.1 Basic Checks

  • MLAB had positive earnings in the past year.
  • In the past year MLAB had a positive cash flow from operations.
  • In multiple years MLAB reported negative net income over the last 5 years.
  • Each year in the past 5 years MLAB had a positive operating cash flow.
MLAB Yearly Net Income VS EBIT VS OCF VS FCFMLAB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100M -200M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 0.86%, MLAB is in the better half of the industry, outperforming 64.91% of the companies in the same industry.
  • MLAB has a better Return On Equity (2.00%) than 66.67% of its industry peers.
  • MLAB has a Return On Invested Capital of 3.58%. This is in the better half of the industry: MLAB outperforms 64.91% of its industry peers.
  • MLAB had an Average Return On Invested Capital over the past 3 years of 2.10%. This is significantly below the industry average of 11.85%.
  • The last Return On Invested Capital (3.58%) for MLAB is above the 3 year average (2.10%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 0.86%
ROE 2%
ROIC 3.58%
ROA(3y)-19.07%
ROA(5y)-11.28%
ROE(3y)-58.62%
ROE(5y)-34.92%
ROIC(3y)2.1%
ROIC(5y)1.72%
MLAB Yearly ROA, ROE, ROICMLAB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100 -150

1.3 Margins

  • The Profit Margin of MLAB (1.51%) is better than 64.91% of its industry peers.
  • MLAB has a better Operating Margin (6.96%) than 61.40% of its industry peers.
  • In the last couple of years the Operating Margin of MLAB has grown nicely.
  • MLAB has a Gross Margin of 62.40%. This is amongst the best in the industry. MLAB outperforms 80.70% of its industry peers.
  • In the last couple of years the Gross Margin of MLAB has grown nicely.
Industry RankSector Rank
OM 6.96%
PM (TTM) 1.51%
GM 62.4%
OM growth 3Y41.92%
OM growth 5Y1.93%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.16%
GM growth 5Y2.74%
MLAB Yearly Profit, Operating, Gross MarginsMLAB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. MLAB Health Analysis

2.1 Basic Checks

  • MLAB has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • Compared to 1 year ago, MLAB has more shares outstanding
  • Compared to 5 years ago, MLAB has more shares outstanding
  • The debt/assets ratio for MLAB has been reduced compared to a year ago.
MLAB Yearly Shares OutstandingMLAB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1M 2M 3M 4M 5M
MLAB Yearly Total Debt VS Total AssetsMLAB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • Based on the Altman-Z score of 1.33, we must say that MLAB is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of 1.33, MLAB perfoms like the industry average, outperforming 43.86% of the companies in the same industry.
  • The Debt to FCF ratio of MLAB is 4.41, which is a neutral value as it means it would take MLAB, 4.41 years of fcf income to pay off all of its debts.
  • MLAB has a better Debt to FCF ratio (4.41) than 71.93% of its industry peers.
  • A Debt/Equity ratio of 0.86 indicates that MLAB is somewhat dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.86, MLAB is doing worse than 78.95% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.86
Debt/FCF 4.41
Altman-Z 1.33
ROIC/WACC0.34
WACC10.55%
MLAB Yearly LT Debt VS Equity VS FCFMLAB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

2.3 Liquidity

  • A Current Ratio of 1.94 indicates that MLAB should not have too much problems paying its short term obligations.
  • The Current ratio of MLAB (1.94) is worse than 64.91% of its industry peers.
  • MLAB has a Quick Ratio of 1.45. This is a normal value and indicates that MLAB is financially healthy and should not expect problems in meeting its short term obligations.
  • MLAB's Quick ratio of 1.45 is on the low side compared to the rest of the industry. MLAB is outperformed by 68.42% of its industry peers.
Industry RankSector Rank
Current Ratio 1.94
Quick Ratio 1.45
MLAB Yearly Current Assets VS Current LiabilitesMLAB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. MLAB Growth Analysis

3.1 Past

  • MLAB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -87.40%.
  • The earnings per share for MLAB have been decreasing by -39.16% on average. This is quite bad
  • Looking at the last year, MLAB shows a small growth in Revenue. The Revenue has grown by 4.12% in the last year.
  • MLAB shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 15.41% yearly.
EPS 1Y (TTM)-87.4%
EPS 3Y-62.71%
EPS 5Y-39.16%
EPS Q2Q%351.94%
Revenue 1Y (TTM)4.12%
Revenue growth 3Y9.35%
Revenue growth 5Y15.41%
Sales Q2Q%3.64%

3.2 Future

  • The Earnings Per Share is expected to grow by 247.51% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 4.11% on average over the next years.
EPS Next Y3244.14%
EPS Next 2Y354.08%
EPS Next 3Y247.51%
EPS Next 5YN/A
Revenue Next Year4.19%
Revenue Next 2Y4.8%
Revenue Next 3Y4.11%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
MLAB Yearly Revenue VS EstimatesMLAB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 50M 100M 150M 200M 250M
MLAB Yearly EPS VS EstimatesMLAB Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

5

4. MLAB Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 125.00 indicates a quite expensive valuation of MLAB.
  • The rest of the industry has a similar Price/Earnings ratio as MLAB.
  • MLAB's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 25.23.
  • MLAB is valuated quite expensively with a Price/Forward Earnings ratio of 55.43.
  • The rest of the industry has a similar Price/Forward Earnings ratio as MLAB.
  • The average S&P500 Price/Forward Earnings ratio is at 23.28. MLAB is valued rather expensively when compared to this.
Industry RankSector Rank
PE 125
Fwd PE 55.43
MLAB Price Earnings VS Forward Price EarningsMLAB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of MLAB indicates a rather cheap valuation: MLAB is cheaper than 84.21% of the companies listed in the same industry.
  • Based on the Price/Free Cash Flow ratio, MLAB is valued cheaply inside the industry as 94.74% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 11.72
EV/EBITDA 13.7
MLAB Per share dataMLAB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of MLAB may justify a higher PE ratio.
  • MLAB's earnings are expected to grow with 247.51% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.04
PEG (5Y)N/A
EPS Next 2Y354.08%
EPS Next 3Y247.51%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. MLAB Dividend Analysis

5.1 Amount

  • MLAB has a yearly dividend return of 0.78%, which is pretty low.
  • MLAB's Dividend Yield is rather good when compared to the industry average which is at 0.11. MLAB pays more dividend than 96.49% of the companies in the same industry.
  • With a Dividend Yield of 0.78, MLAB pays less dividend than the S&P500 average, which is at 1.89.
Industry RankSector Rank
Dividend Yield 0.78%

5.2 History

  • The dividend of MLAB decreases each year by -0.50%.
  • MLAB has been paying a dividend for at least 10 years, so it has a reliable track record.
  • MLAB has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.
Dividend Growth(5Y)-0.5%
Div Incr Years0
Div Non Decr Years21
MLAB Yearly Dividends per shareMLAB Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0.2 0.4 0.6

5.3 Sustainability

  • MLAB pays out 93.97% of its income as dividend. This is not a sustainable payout ratio.
DP93.97%
EPS Next 2Y354.08%
EPS Next 3Y247.51%
MLAB Yearly Income VS Free CF VS DividendMLAB Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50M -100M -150M -200M -250M
MLAB Dividend Payout.MLAB Dividend Payout, showing the Payout Ratio.MLAB Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

MLAB Fundamentals: All Metrics, Ratios and Statistics

MESA LABORATORIES INC

NASDAQ:MLAB (3/20/2026, 8:10:39 PM)

After market: 80 0 (0%)

80

-2.52 (-3.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-03
Earnings (Next)05-26
Inst Owners92.09%
Inst Owner Change-4%
Ins Owners5.44%
Ins Owner Change3.15%
Market Cap441.60M
Revenue(TTM)247.54M
Net Income(TTM)3.73M
Analysts80
Price Target106.59 (33.24%)
Short Float %4.49%
Short Ratio2.04
Dividend
Industry RankSector Rank
Dividend Yield 0.78%
Yearly Dividend0.64
Dividend Growth(5Y)-0.5%
DP93.97%
Div Incr Years0
Div Non Decr Years21
Ex-Date02-27
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)153.03%
Min EPS beat(2)130.33%
Max EPS beat(2)175.74%
EPS beat(4)3
Avg EPS beat(4)44.77%
Min EPS beat(4)-217.83%
Max EPS beat(4)175.74%
EPS beat(8)5
Avg EPS beat(8)420.17%
EPS beat(12)6
Avg EPS beat(12)229.7%
EPS beat(16)8
Avg EPS beat(16)172.52%
Revenue beat(2)1
Avg Revenue beat(2)-0.59%
Min Revenue beat(2)-1.95%
Max Revenue beat(2)0.77%
Revenue beat(4)1
Avg Revenue beat(4)-1.45%
Min Revenue beat(4)-3.63%
Max Revenue beat(4)0.77%
Revenue beat(8)4
Avg Revenue beat(8)0.47%
Revenue beat(12)4
Avg Revenue beat(12)-1.22%
Revenue beat(16)6
Avg Revenue beat(16)-1.01%
PT rev (1m)5.56%
PT rev (3m)10%
EPS NQ rev (1m)-10.53%
EPS NQ rev (3m)-3.77%
EPS NY rev (1m)19.12%
EPS NY rev (3m)19.12%
Revenue NQ rev (1m)0.55%
Revenue NQ rev (3m)1.07%
Revenue NY rev (1m)1.06%
Revenue NY rev (3m)1.06%
Valuation
Industry RankSector Rank
PE 125
Fwd PE 55.43
P/S 1.78
P/FCF 11.72
P/OCF 10.63
P/B 2.37
P/tB N/A
EV/EBITDA 13.7
EPS(TTM)0.64
EY0.8%
EPS(NY)1.44
Fwd EY1.8%
FCF(TTM)6.83
FCFY8.54%
OCF(TTM)7.52
OCFY9.41%
SpS44.84
BVpS33.82
TBVpS-16.71
PEG (NY)0.04
PEG (5Y)N/A
Graham Number22.07
Profitability
Industry RankSector Rank
ROA 0.86%
ROE 2%
ROCE 4.53%
ROIC 3.58%
ROICexc 3.87%
ROICexgc 18.77%
OM 6.96%
PM (TTM) 1.51%
GM 62.4%
FCFM 15.23%
ROA(3y)-19.07%
ROA(5y)-11.28%
ROE(3y)-58.62%
ROE(5y)-34.92%
ROIC(3y)2.1%
ROIC(5y)1.72%
ROICexc(3y)2.32%
ROICexc(5y)2.16%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)2.66%
ROCE(5y)2.18%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y111.19%
ROICexc growth 5Y22.93%
OM growth 3Y41.92%
OM growth 5Y1.93%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.16%
GM growth 5Y2.74%
F-Score6
Asset Turnover0.57
Health
Industry RankSector Rank
Debt/Equity 0.86
Debt/FCF 4.41
Debt/EBITDA 3.81
Cap/Depr 15.35%
Cap/Sales 1.55%
Interest Coverage 250
Cash Conversion 98.31%
Profit Quality 1009.48%
Current Ratio 1.94
Quick Ratio 1.45
Altman-Z 1.33
F-Score6
WACC10.55%
ROIC/WACC0.34
Cap/Depr(3y)13.3%
Cap/Depr(5y)13.77%
Cap/Sales(3y)1.71%
Cap/Sales(5y)1.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-87.4%
EPS 3Y-62.71%
EPS 5Y-39.16%
EPS Q2Q%351.94%
EPS Next Y3244.14%
EPS Next 2Y354.08%
EPS Next 3Y247.51%
EPS Next 5YN/A
Revenue 1Y (TTM)4.12%
Revenue growth 3Y9.35%
Revenue growth 5Y15.41%
Sales Q2Q%3.64%
Revenue Next Year4.19%
Revenue Next 2Y4.8%
Revenue Next 3Y4.11%
Revenue Next 5YN/A
EBIT growth 1Y-4.88%
EBIT growth 3Y55.19%
EBIT growth 5Y17.63%
EBIT Next Year193.28%
EBIT Next 3Y47.61%
EBIT Next 5YN/A
FCF growth 1Y-7.43%
FCF growth 3Y6.74%
FCF growth 5Y10.67%
OCF growth 1Y-5.11%
OCF growth 3Y6.07%
OCF growth 5Y11.64%

MESA LABORATORIES INC / MLAB Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for MESA LABORATORIES INC?

ChartMill assigns a fundamental rating of 5 / 10 to MLAB.


What is the valuation status of MESA LABORATORIES INC (MLAB) stock?

ChartMill assigns a valuation rating of 5 / 10 to MESA LABORATORIES INC (MLAB). This can be considered as Fairly Valued.


How profitable is MESA LABORATORIES INC (MLAB) stock?

MESA LABORATORIES INC (MLAB) has a profitability rating of 7 / 10.


What is the financial health of MESA LABORATORIES INC (MLAB) stock?

The financial health rating of MESA LABORATORIES INC (MLAB) is 3 / 10.


Can you provide the expected EPS growth for MLAB stock?

The Earnings per Share (EPS) of MESA LABORATORIES INC (MLAB) is expected to grow by 3244.14% in the next year.